Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization
文献类型：期刊论文
| 作者 | Fu, Shujun1; Zhu, Xueran2; Huang, Fanghua1; Chen, Xiaoyan2 |
| 刊名 | PHARMACEUTICS
 |
| 出版日期 | 2025-08-20 |
| 卷号 | 17期号:8页码:22 |
| 关键词 | anti-PEG antibodies pre-existing anti-PEG antibodies immunogenicity ABC effect biological effects |
| DOI | 10.3390/pharmaceutics17081074 |
| 英文摘要 | Polyethylene glycol (PEG) has been widely utilized in optimizing therapeutics due to its excellent biocompatibility and chemical stability. However, multiple dosing of PEGylated drugs may result in toxicity due to PEG accumulation in tissues, leading to the formation of anti-PEG antibodies (APAs), which can accelerate drug clearance, reduce efficacy, and alongside enhanced side effects, such as allergic reactions. Notably, pre-existing APAs have also been detected in individuals with no prior exposure to PEGylated drugs, raising additional clinical concerns. This review summarizes the mechanisms of APA generation, the factors influencing PEG immunogenicity, and the biological consequences of APAs on drug pharmacokinetics, efficacy, and safety. We also discuss current challenges in APA detection and highlight strategies to minimize immunogenic responses, including PEG modification, immunomodulation, and alternative polymers. This review aims to provide a comprehensive reference for the rational design, evaluation, and clinical management of PEGylated drugs. |
| WOS关键词 | ACCELERATED BLOOD CLEARANCE ; POLYETHYLENE-GLYCOL PEG ; ABC PHENOMENON ; LIPOSOMAL DOXORUBICIN ; POLY(ETHYLENE GLYCOL) ; IGM ANTIBODIES ; PHARMACOKINETICS ; IMMUNOGENICITY ; NANOPARTICLES ; IMMUNOASSAYS |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001557513400001 |
| 出版者 | MDPI |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/321336]  |
| 专题 | 国家级研究中心_原创新药研究全国重点实验室 |
| 通讯作者 | Huang, Fanghua; Chen, Xiaoyan |
| 作者单位 | 1.Natl Med Prod Adm, Ctr Drug Evaluat, Beijing 100076, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Fu, Shujun,Zhu, Xueran,Huang, Fanghua,et al. Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization[J]. PHARMACEUTICS,2025,17(8):22. |
| APA | Fu, Shujun,Zhu, Xueran,Huang, Fanghua,&Chen, Xiaoyan.(2025).Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization.PHARMACEUTICS,17(8),22. |
| MLA | Fu, Shujun,et al."Anti-PEG Antibodies and Their Biological Impact on PEGylated Drugs: Challenges and Strategies for Optimization".PHARMACEUTICS 17.8(2025):22. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。